These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6791053)

  • 41. Hyperammonemia associated with valproic acid use in elderly psychiatric patients.
    Holroyd S; Overdyke JT
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):372-4. PubMed ID: 23037652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Valproic Acid-Associated Hyperammonemia: A Systematic Review.
    Wong YJ; Fan J; Wan A; Mihic T; Gnyra M
    J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):283-294. PubMed ID: 37126830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
    Panda S; Radhakrishnan K
    J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Ring chromosome 20, hypersensitivity to valproate and hyperammonemic encephalopathy].
    Ortiz-Sáenz de Santa María MR; Barriuso-Pérez E; Soto-Alvarez MI; Moche-Loeri JA
    Rev Neurol; 2003 Oct 16-31; 37(8):733-5. PubMed ID: 14593631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Valproate-induced hyperammonemia in asymptomatic children.
    Wyllie E; Wyllie R; Rothner AD; Erenberg G; Cruse RP
    Cleve Clin Q; 1983; 50(3):275-7. PubMed ID: 6418412
    [No Abstract]   [Full Text] [Related]  

  • 46. Standardization in VPA-induced hyperammonemia.
    Zaret BS; Marini AM
    Neurology; 1985 Jan; 35(1):136-7. PubMed ID: 3917561
    [No Abstract]   [Full Text] [Related]  

  • 47. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.
    Zaccara G; Campostrini R; Paganini M; Moroni F; Valenza T; Targioni G; Arnetoli G; Zappoli R; Baruzzi A
    Neurology; 1984 Nov; 34(11):1519-21. PubMed ID: 6436733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of epileptic patients with valproic acid does not modify plasma and urine short-chain-fatty acids.
    Zaccara G; Boncinelli L; Paganini M; Campostrini R; Arnetoli G; Zappoli R
    Acta Neurol Scand; 1983 Oct; 68(4):241-7. PubMed ID: 6419536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carnitine for valproic acid-induced hyperammonemia.
    Raby WN
    Am J Psychiatry; 1997 Aug; 154(8):1168-9. PubMed ID: 9247410
    [No Abstract]   [Full Text] [Related]  

  • 50. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients.
    Thomas KL; La AQ; Punia S; Doroudgar S; Perry PJ
    Ann Clin Psychiatry; 2016 Feb; 28(1):37-42. PubMed ID: 26855984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
    Cheng M; Tang X; Wen S; Yue J; Wang H
    Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Carglumic acid for treatment of valproic acid-induced hyperammonaemia in a paediatric patient].
    Gramage Caro T; Vélez-Díaz-Pallarés M; Serna Pérez J; Bermejo Vicedo T
    Farm Hosp; 2012; 36(5):437-8. PubMed ID: 22858088
    [No Abstract]   [Full Text] [Related]  

  • 55. [Hyperammonaemic encephalopathy due to valproic acid in the neonatal period].
    Jiménez-Parrilla F; Pérez-Sánchez A; Núñez-Solís JM; Madruga-Garrido M; Losada-Martínez A
    Rev Neurol; 2009 Jun 1-15; 48(11):613-4. PubMed ID: 19472163
    [No Abstract]   [Full Text] [Related]  

  • 56. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?
    Chicharro AV; de Marinis AJ; Kanner AM
    Epilepsy Behav; 2007 Nov; 11(3):361-6. PubMed ID: 17845866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Valproic acid-induced hyperammonemia in mentally retarded adults.
    Williams CA; Tiefenbach S; McReynolds JW
    Neurology; 1984 Apr; 34(4):550-3. PubMed ID: 6422325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
    Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
    J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
    Hosseini H; Shafie M; Shakiba A; Ghayyem H; Mayeli M; Hassani M; Aghamollaii V
    Psychopharmacology (Berl); 2023 Jan; 240(1):149-156. PubMed ID: 36459199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.